Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Parabilis Medicines, Inc. ( PBLS ) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 2:35 PM EDT Company Participants Mathai Mammen - CEO, President, Treasurer & Chairman Presentation Unknown Analyst Hi everyone. Very happy to be joined by Mathai Mammen, the CEO and Chairman of Parabilis. Thank you for joining us on day 3 of the Morgan Stanley Healthcare Conference. Thanks for being with us, Mathai. Mathai Mammen CEO, President, Treasurer & Chairman Of course, I appreciate it. Unknown Analyst Just a quick disclaimer. Please visit morganstanley.com/researchdisclosures for important disclosures relating to our conference. Question-and-Answer Session Unknown Analyst So let's start with the Parabilis story at a high level, maybe you can take us back to the founding of the company and the original insight behind the Helicon platform. What problem in drug discovery were you trying to solve that conventional small molecules and antibodies couldn't address? Mathai Mammen CEO, President, Treasurer & Chairman Yes. Thanks for that question. The company was founded by a Harvard professor called Greg Verdine, who was the same professor behind Warp Drive that got folded into Revolution Medicines. That's the basis of their product now and Warp Drive and other companies as well. The problem he had been thinking about for a long time is one of druggability, undruggability that most proteins inside cells lack small molecule binding pockets. Pockets are required for any kind of small molecule or version of a small molecule we have today from degraders to covalents to anything. So what to do then because 80% or so of proteins inside cells lack these. And yet the genetics and phenotypic screening efforts that are abound in the industry now, they often point to one of those 80% as causes of various diseases. So if that's a cause, you're kind of